User login
Key clinical point: Cessation of calcitonin gene‐related peptide-receptor (CGRP-R) monoclonal antibody (mAb) prophylaxis worsens headache impact and health-related quality of life in patients with migraine.
Main finding: After 16 weeks from the last mAb injection, the mean Headache Impact Test-6 sum score increased by 3.69 (P < .001), mean EuroQol-5-Dimension-5-level declined by −0.07 (P = .013) and mean physical and mental component summary of Short Form-12 score deteriorated by −4.04 (P = .013) and −2.73 (P = .003), respectively.
Study details: This was a longitudinal, prospective cohort study involving 61 adult patients with episodic/chronic migraine receiving prophylaxis with a CGRP-R mAb (erenumab, n = 29; galcanezumab/fremanezumab, n = 32) for ≥8 months before a planned treatment cessation attempt.
Disclosures: The authors did not receive any financial support for the study. Some of the authors, including the lead author, reported serving on the advisory board of or receiving personal fees, speaker/consultant honoraria, and research grants from various organizations.
Source: Terhart M et al. J Headache Pain. 2021;22:158 (Dec 31). Doi: 10.1186/s10194-021-01368-7.
Key clinical point: Cessation of calcitonin gene‐related peptide-receptor (CGRP-R) monoclonal antibody (mAb) prophylaxis worsens headache impact and health-related quality of life in patients with migraine.
Main finding: After 16 weeks from the last mAb injection, the mean Headache Impact Test-6 sum score increased by 3.69 (P < .001), mean EuroQol-5-Dimension-5-level declined by −0.07 (P = .013) and mean physical and mental component summary of Short Form-12 score deteriorated by −4.04 (P = .013) and −2.73 (P = .003), respectively.
Study details: This was a longitudinal, prospective cohort study involving 61 adult patients with episodic/chronic migraine receiving prophylaxis with a CGRP-R mAb (erenumab, n = 29; galcanezumab/fremanezumab, n = 32) for ≥8 months before a planned treatment cessation attempt.
Disclosures: The authors did not receive any financial support for the study. Some of the authors, including the lead author, reported serving on the advisory board of or receiving personal fees, speaker/consultant honoraria, and research grants from various organizations.
Source: Terhart M et al. J Headache Pain. 2021;22:158 (Dec 31). Doi: 10.1186/s10194-021-01368-7.
Key clinical point: Cessation of calcitonin gene‐related peptide-receptor (CGRP-R) monoclonal antibody (mAb) prophylaxis worsens headache impact and health-related quality of life in patients with migraine.
Main finding: After 16 weeks from the last mAb injection, the mean Headache Impact Test-6 sum score increased by 3.69 (P < .001), mean EuroQol-5-Dimension-5-level declined by −0.07 (P = .013) and mean physical and mental component summary of Short Form-12 score deteriorated by −4.04 (P = .013) and −2.73 (P = .003), respectively.
Study details: This was a longitudinal, prospective cohort study involving 61 adult patients with episodic/chronic migraine receiving prophylaxis with a CGRP-R mAb (erenumab, n = 29; galcanezumab/fremanezumab, n = 32) for ≥8 months before a planned treatment cessation attempt.
Disclosures: The authors did not receive any financial support for the study. Some of the authors, including the lead author, reported serving on the advisory board of or receiving personal fees, speaker/consultant honoraria, and research grants from various organizations.
Source: Terhart M et al. J Headache Pain. 2021;22:158 (Dec 31). Doi: 10.1186/s10194-021-01368-7.